Attached files
file | filename |
---|---|
EX-99 - LETTER TO SHAREHOLDERS - H-CYTE, INC. | ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
____________________________________________________________
Date of
Report (Date of earliest event reported): June 12, 2017
MEDOVEX CORP.
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
001-36763
|
|
46-3312262
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
1950
Airport Road, Suite A
Atlanta, Georgia
|
|
|
|
30341
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
|
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Friedman Kesner LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
□
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
2(b))
□
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
FORWARD-LOOKING STATEMENTS
This Current Report on Form 8-K contains forward-looking
statements. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that
are other than statements of historical facts. These statements are
subject to uncertainties and risks including, but not limited to
(i) securing capital for general working purposes, and (ii) other
risks and in statements filed from time to time with the Securities
and Exchange Commission (the “SEC”). All such forward-looking statements,
whether written or oral, and whether made by or on behalf of the
Company, are expressly qualified by the cautionary statements and
any other cautionary statements which may accompany the
forward-looking statements. In addition, the Company disclaims any
obligation to, and will not, update any forward-looking statements
to reflect events or circumstances after the date
hereof.
Item 7.01 Regulation FD
Disclosure
On June 12, 2017, Medovex Corp. (the “Company”) issued a letter (the
“Letter”) updating shareholders regarding certain
developments including receipt of both ISO 13485 Certification and
CE Mark approval for the DenerveX System allowing for the Company
to now commence selling and marketing the DenerveX System in Europe
and other countries that accept the CE Mark. A copy of the
Letter is attached hereto and incorporated herein by reference in
its entirety as Exhibit
99.1.
The information contained in this Current Report on Form 8-K shall
not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
“Securities
Act”) or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing. The furnishing of the information in
this Current Report on Form 8-K is not intended to, and does not,
constitute a representation that such furnishing is required by
Regulation FD or that the information contained in this Current
Report on Form 8-K constitutes material investor information that
is not otherwise publicly available.
The Securities and Exchange Commission encourages registrants to
disclose forward-looking information so that investors can better
understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and exhibits
may contain these types of statements, which are
“forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, and which involve
risks, uncertainties and reflect the Registrant’s judgment as
of the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results and
are indicated by words or phrases such as “expects,”
“should,” “will,” and similar words or
phrases. These statements are subject to inherent uncertainties and
risks that could cause actual results to differ materially from
those anticipated at the date of this Current Report on Form 8-K.
Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented
within.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
Letter
to Shareholders dated June 12, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
Date: June
12, 2017
|
MEDOVEX
CORPORATION
By: /s/
Jarrett Gorlin
Jarrett Gorlin
Chief Executive Officer
|
|
|